Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
Trial ID or NCT#
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
- Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -
Contact us to find out if this trial is right for you.
Theodore Leng, MD